{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T06:50:41Z","timestamp":1750143041036,"version":"3.37.3"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,3,10]],"date-time":"2024-03-10T00:00:00Z","timestamp":1710028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,10]],"date-time":"2024-03-10T00:00:00Z","timestamp":1710028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004564","name":"Ministarstvo Prosvete, Nauke i Tehnolo\u0161kog Razvoja","doi-asserted-by":"publisher","award":["451-03-47\/2023-01\/200111"],"award-info":[{"award-number":["451-03-47\/2023-01\/200111"]}],"id":[{"id":"10.13039\/501100004564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s13318-024-00885-5","type":"journal-article","created":{"date-parts":[[2024,3,10]],"date-time":"2024-03-10T09:01:23Z","timestamp":1710061283000},"page":"277-293","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Anti-calcitonin Gene-Related Peptide Monoclonal Antibodies in Migraine: Focus on Clinical Pharmacokinetics"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1519-8828","authenticated-orcid":false,"given":"Slobodan M.","family":"Jankovi\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sne\u017eana V.","family":"Jankovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,10]]},"reference":[{"issue":"4","key":"885_CR1","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1152\/physrev.00034.2013","volume":"94","author":"FA Russell","year":"2014","unstructured":"Russell FA, King R, Smillie SJ, Kodji X, Brain SD. Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev. 2014;94(4):1099\u2013142.","journal-title":"Physiol Rev"},{"key":"885_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2022.833645","volume":"13","author":"F Argunhan","year":"2022","unstructured":"Argunhan F, Brain SD. The vascular-dependent and -independent actions of calcitonin gene-related peptide in cardiovascular disease. Front Physiol. 2022;13: 833645. https:\/\/doi.org\/10.3389\/fphys.2022.833645.","journal-title":"Front Physiol"},{"key":"885_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173205","volume":"881","author":"I Sohn","year":"2020","unstructured":"Sohn I, Sheykhzade M, Edvinsson L, Sams A. The effects of CGRP in vascular tissue\u2014classical vasodilation, shadowed effects and systemic dilemmas. Eur J Pharmacol. 2020;881: 173205.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"885_CR4","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s10194-017-0741-2","volume":"18","author":"WS Schou","year":"2017","unstructured":"Schou WS, Ashina S, Amin FM, Goadsby PJ, Ashina M. Calcitonin gene-related peptide and pain: a systematic review. J Headache Pain. 2017;18(1):34.","journal-title":"J Headache Pain"},{"issue":"4","key":"885_CR5","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1097\/j.pain.0000000000000831","volume":"158","author":"S Iyengar","year":"2017","unstructured":"Iyengar S, Ossipov MH, Johnson KW. The role of calcitonin gene-related peptide in peripheral and central pain mechanisms including migraine. Pain. 2017;158(4):543\u201359.","journal-title":"Pain"},{"issue":"1","key":"885_CR6","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s10194-023-01656-4","volume":"24","author":"HM Al-Khazali","year":"2023","unstructured":"Al-Khazali HM, Ashina H, Wiggers A, Rose K, Iljazi A, Christensen RH, et al. Calcitonin gene-related peptide causes migraine aura. J Headache Pain. 2023;24(1):124.","journal-title":"J Headache Pain"},{"issue":"4","key":"885_CR7","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/head.14103","volume":"61","author":"DC Buse","year":"2021","unstructured":"Buse DC, Armand CE, Charleston L IV, Reed ML, Fanning KM, Adams AM, et al. Barriers to care in episodic and chronic migraine: results from the chronic migraine epidemiology and outcomes study. Headache J Head Face Pain. 2021;61(4):628\u201341.","journal-title":"Headache J Head Face Pain."},{"issue":"4","key":"885_CR8","doi-asserted-by":"publisher","first-page":"033310242311593","DOI":"10.1177\/03331024231159366","volume":"43","author":"F Haghdoost","year":"2023","unstructured":"Haghdoost F, Puledda F, Garcia-Azorin D, Huessler EM, Messina R, Pozo-Rosich P. Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: a systematic review and network meta-analysis of phase 3 randomised controlled trials. Cephalalgia. 2023;43(4):03331024231159366.","journal-title":"Cephalalgia"},{"issue":"1","key":"885_CR9","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s10194-023-01611-3","volume":"24","author":"N Vandenbussche","year":"2023","unstructured":"Vandenbussche N, Pisarek K, Paemeleire K. Methodological considerations on real-world evidence studies of monoclonal antibodies against the CGRP-pathway for migraine: a systematic review. J Headache Pain. 2023;24(1):75.","journal-title":"J Headache Pain"},{"issue":"1","key":"885_CR10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s10194-023-01637-7","volume":"24","author":"J Schoenen","year":"2023","unstructured":"Schoenen J, Van Dycke A, Versijpt J, Paemeleire K. Ten open questions in migraine prophylaxis with monoclonal antibodies blocking the calcitonin-gene related peptide pathway: a narrative review. J Headache Pain. 2023;24(1):99.","journal-title":"J Headache Pain"},{"issue":"1","key":"885_CR11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s10194-023-01602-4","volume":"24","author":"L Al-Hassany","year":"2023","unstructured":"Al-Hassany L, Karsan N, Lampl C, Goadsby PJ, MaassenVanDenBrink A. Revisiting dose-finding of monoclonal antibodies in migraine. J Headache Pain. 2023;24(1):69.","journal-title":"J Headache Pain"},{"key":"885_CR12","doi-asserted-by":"publisher","first-page":"251581632312073","DOI":"10.1177\/25158163231207322","volume":"6","author":"S Suzuki","year":"2023","unstructured":"Suzuki S, Suzuki K, Shiina T, Haruyama Y, Hirata K. Evaluating the wearing-off effects of fremanezumab in high-frequency episodic migraine and chronic migraine: a real-world observational study in Japan. Cephalalgia Rep. 2023;6:25158163231207320.","journal-title":"Cephalalgia Rep."},{"issue":"2","key":"885_CR13","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S1474-4422(17)30435-0","volume":"17","author":"A Charles","year":"2018","unstructured":"Charles A. The pathophysiology of migraine: implications for clinical management. Lancet Neurol. 2018;17(2):174\u201382.","journal-title":"Lancet Neurol"},{"issue":"1","key":"885_CR14","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s10194-023-01569-2","volume":"24","author":"A Kuburas","year":"2023","unstructured":"Kuburas A, Russo AF. Shared and independent roles of CGRP and PACAP in migraine pathophysiology. J Headache Pain. 2023;24(1):34.","journal-title":"J Headache Pain"},{"issue":"4","key":"885_CR15","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1097\/WNO.0000000000000875","volume":"39","author":"C Chan","year":"2019","unstructured":"Chan C, Wei DY, Goadsby PJ. Biochemical modulation and pathophysiology of migraine. J Neuroophthalmol. 2019;39(4):470\u20139.","journal-title":"J Neuroophthalmol"},{"issue":"3","key":"885_CR16","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.pharmthera.2009.09.003","volume":"124","author":"CM Villal\u00f3n","year":"2009","unstructured":"Villal\u00f3n CM, Olesen J. The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs. Pharmacol Ther. 2009;124(3):309\u201323.","journal-title":"Pharmacol Ther"},{"issue":"5","key":"885_CR17","first-page":"390","volume":"37","author":"S Santos-Lasaosa","year":"2022","unstructured":"Santos-Lasaosa S, Belv\u00eds R, Cuadrado ML, D\u00edaz-Insa S, Gago-Veiga A, Guerrero-Peral AL, et al. Calcitonin gene-related peptide in migraine: from pathophysiology to treatment. Neurol Engl Ed. 2022;37(5):390\u2013402.","journal-title":"Neurol Engl Ed."},{"issue":"7","key":"885_CR18","doi-asserted-by":"publisher","first-page":"3654","DOI":"10.1007\/s00415-023-11706-1","volume":"270","author":"F Puledda","year":"2023","unstructured":"Puledda F, Silva EM, Suwanlaong K, Goadsby PJ. Migraine: from pathophysiology to treatment. J Neurol. 2023;270(7):3654\u201366.","journal-title":"J Neurol"},{"issue":"3","key":"885_CR19","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1007\/s13311-022-01230-x","volume":"19","author":"F Cohen","year":"2022","unstructured":"Cohen F, Yuan H, DePoy EMG, Silberstein SD. The arrival of anti-CGRP monoclonal antibodies in migraine. Neurotherapeutics. 2022;19(3):922\u201330.","journal-title":"Neurotherapeutics"},{"issue":"1","key":"885_CR20","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s10194-023-01644-8","volume":"24","author":"A Labastida-Ram\u00edrez","year":"2023","unstructured":"Labastida-Ram\u00edrez A, Caronna E, Gollion C, Stanyer E, Dapkute A, Braniste D, et al. Mode and site of action of therapies targeting CGRP signaling. J Headache Pain. 2023;24(1):125.","journal-title":"J Headache Pain"},{"issue":"1","key":"885_CR21","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S1359-6446(05)03638-X","volume":"11","author":"MA Tabrizi","year":"2006","unstructured":"Tabrizi MA, Tseng CML, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today. 2006;11(1):81\u20138.","journal-title":"Drug Discov Today"},{"issue":"8","key":"885_CR22","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2165\/11531280-000000000-00000","volume":"49","author":"RJ Keizer","year":"2010","unstructured":"Keizer RJ, Huitema ADR, Schellens JHM, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(8):493\u2013507.","journal-title":"Clin Pharmacokinet"},{"key":"885_CR23","doi-asserted-by":"publisher","first-page":"740","DOI":"10.3389\/fphar.2017.00740","volume":"8","author":"D Monteith","year":"2017","unstructured":"Monteith D, Collins EC, Vandermeulen C, Van Hecken A, Raddad E, Scherer JC, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the cgrp binding monoclonal antibody LY2951742 (galcanezumab) in healthy volunteers. Front Pharmacol. 2017;8:740.","journal-title":"Front Pharmacol"},{"key":"885_CR24","first-page":"247","volume":"33","author":"J de Hoon","year":"2013","unstructured":"de Hoon J, Montieth D, Vermeersch S, Van Hecken A, Abu-Raddad E, Collins E, et al. Safety, pharmacokinetics, and pharmacodynamics of LY2951742: a monoclonal antibody targeting CGRP. Cephalalgia. 2013;33:247\u20138.","journal-title":"Cephalalgia"},{"issue":"4","key":"885_CR25","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3999\/jscpt.48.131","volume":"48","author":"M Nakano","year":"2017","unstructured":"Nakano M, Uenaka K, Kielbasa W, Matsuyama Y, Ozeki A, Ayan-Oshodi MA. Safety, tolerability, pharmacokinetics, and pharmacodynamics of galcanezumab, a monoclonal antibody to calcitonin gene-related peptide, in healthy Japanese and Caucasian subjects. Rinsh\u03bf Yakuri Jpn J Clin Pharmacol Ther. 2017;48(4):131\u20139.","journal-title":"Rinsh\u03bf Yakuri Jpn J Clin Pharmacol Ther."},{"key":"885_CR26","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.2147\/PPA.S170636","volume":"12","author":"VL Stauffer","year":"2018","unstructured":"Stauffer VL, Sides R, Lanteri-Minet M, Kielbasa W, Jin Y, Selzler KJ, et al. Comparison between prefilled syringe and autoinjector devices on patient-reported experiences and pharmacokinetics in galcanezumab studies. Patient Prefer Adherence. 2018;12:1785\u201395.","journal-title":"Patient Prefer Adherence"},{"key":"885_CR27","unstructured":"Kielbasa W, Williams DW, Coutant DE, King A, Ayan\u2010Oshodi MA.Kielbasa W, Williams DW, Coutant DE, King A, Ayan\u2010Oshodi MA. Tolerability, pharmacokinetics, and pharmacodynamics of galcanezumab in healthy subjects following a subcutaneous administration of a lyophilized formulation or a solution formulation. In: 59th annual scientific meeting of the american headache society. Boston, MA; 2017."},{"key":"885_CR28","unstructured":"A randomized, placebo-controlled, single-dose study to assess the pharmacokinetics, safety, and tolerability of galcanezumab in healthy Chinese subjects. https:\/\/clinicaltrials.gov\/study\/NCT04085289. Accessed 1 Jan 2024."},{"issue":"2","key":"885_CR29","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/jcph.1511","volume":"60","author":"W Kielbasa","year":"2020","unstructured":"Kielbasa W, Quinlan T. Population pharmacokinetics of galcanezumab, an anti-CGRP antibody, following subcutaneous dosing to healthy individuals and patients with migraine. J Clin Pharmacol. 2020;60(2):229\u201339.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"885_CR30","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s10194-020-01148-9","volume":"21","author":"VL Stauffer","year":"2020","unstructured":"Stauffer VL, Turner I, Kemmer P, Kielbasa W, Day K, Port M, et al. Effect of age on pharmacokinetics, efficacy, and safety of galcanezumab treatment in adult patients with migraine: results from six phase 2 and phase 3 randomized clinical trials. J Headache Pain. 2020;21(1):79.","journal-title":"J Headache Pain"},{"issue":"5","key":"885_CR31","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1002\/cpt.799","volume":"103","author":"J de Hoon","year":"2018","unstructured":"de Hoon J, Van Hecken A, Vandermeulen C, Yan L, Smith B, Chen JS, et al. Phase I, randomized, double-blind, placebo-controlled, single-dose, and multiple-dose studies of erenumab in healthy subjects and patients with migraine. Clin Pharmacol Ther. 2018;103(5):815\u201325.","journal-title":"Clin Pharmacol Ther"},{"key":"885_CR32","unstructured":"Phase 1, randomized, double-blind, placebo-controlled, ascending multiple-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AMG 334 in healthy subjects and in migraine patients. https:\/\/clinicaltrials.gov\/study\/NCT01723514. Accessed 1 Jan 2024."},{"issue":"9","key":"885_CR33","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1007\/s11095-017-2183-6","volume":"34","author":"T Vu","year":"2017","unstructured":"Vu T, Ma P, Chen JS, de Hoon J, Van Hecken A, Yan L, et al. Pharmacokinetic\u2013pharmacodynamic relationship of erenumab (AMG 334) and Capsaicin-induced dermal blood flow in healthy and migraine subjects. Pharm Res. 2017;34(9):1784\u201395.","journal-title":"Pharm Res"},{"issue":"7","key":"885_CR34","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s40261-022-01171-5","volume":"42","author":"Q Shen","year":"2022","unstructured":"Shen Q, Jin Y, Di X, Hu C, Liu R, Wang Y, et al. Pharmacokinetics and safety of erenumab after a single subcutaneous injection dose in healthy Chinese subjects. Clin Drug Investig. 2022;42(7):623\u201330.","journal-title":"Clin Drug Investig"},{"key":"885_CR35","unstructured":"Randomized, stratified, parallel-group, double-blind, placebo-controlled, study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of AMG 334 in women with hot flashes associated with menopause. https:\/\/clinicaltrials.gov\/study\/NCT01890109. Accessed 31 Jan 2024."},{"key":"885_CR36","unstructured":"Phase I, randomized, parallel-group, double-blind, placebo-controlled, single dose study to evaluate the blockade of CGRP receptor by AMG 334 in preventing PACAP-38 induced migraine-like attacks in migraine patients. https:\/\/clinicaltrials.gov\/study\/NCT02542605. Accessed 2 Feb 2024."},{"key":"885_CR37","doi-asserted-by":"publisher","first-page":"251581632211313","DOI":"10.1177\/25158163221131326","volume":"5","author":"B Baker","year":"2022","unstructured":"Baker B, Shen V, Cady R, Ettrup A, Larsen F. Eptinezumab administered intravenously, subcutaneously, or intramuscularly in healthy subjects and\/or patients with migraine: early development studies. Cephalalgia Rep. 2022;5:25158163221131330.","journal-title":"Cephalalgia Rep."},{"issue":"2","key":"885_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.567","volume":"8","author":"B Baker","year":"2020","unstructured":"Baker B, Schaeffler B, Beliveau M, Rubets I, Pederson S, Trinh M, et al. Population pharmacokinetic and exposure-response analysis of eptinezumab in the treatment of episodic and chronic migraine. Pharmacol Res Perspect. 2020;8(2): e00567.","journal-title":"Pharmacol Res Perspect"},{"issue":"Suppl 1","key":"885_CR39","first-page":"109","volume":"37","author":"B Baker","year":"2017","unstructured":"Baker B, Schaeffler B, Cady R, Latham J, Whitaker T, Smith J. Rational design of a monoclonal antibody inhibiting calcitonin gene-related peptide, ALD403 (eptinezumab), to provide early onset, high efficacy, extended duration of action, and desired safety for the prevention of migraine. Cephalgia. 2017;37(Suppl 1):109.","journal-title":"Cephalgia."},{"issue":"9","key":"885_CR40","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1177\/0333102419858355","volume":"39","author":"DW Dodick","year":"2019","unstructured":"Dodick DW, Lipton RB, Silberstein S, Goadsby PJ, Biondi D, Hirman J, et al. Eptinezumab for prevention of chronic migraine: a randomized phase 2b clinical trial. Cephalalgia Int J Headache. 2019;39(9):1075\u201385.","journal-title":"Cephalalgia Int J Headache."},{"issue":"7","key":"885_CR41","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1177\/0333102413517775","volume":"34","author":"ME Bigal","year":"2014","unstructured":"Bigal ME, Escandon R, Bronson M, Walter S, Sudworth M, Huggins JP, et al. Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: results of the phase 1 program. Cephalalgia Int J Headache. 2014;34(7):483\u201392.","journal-title":"Cephalalgia Int J Headache."},{"issue":"2","key":"885_CR42","first-page":"324","volume":"15","author":"B Raffaelli","year":"2018","unstructured":"Raffaelli B, Reuter U. The biology of monoclonal antibodies: focus on calcitonin gene-related peptide for prophylactic migraine therapy. Neurother J Am Soc Exp Neurother. 2018;15(2):324\u201335.","journal-title":"Neurother J Am Soc Exp Neurother."},{"issue":"13","key":"885_CR43","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1177\/0333102418771376","volume":"38","author":"O Cohen-Barak","year":"2018","unstructured":"Cohen-Barak O, Weiss S, Rasamoelisolo M, Faulhaber N, Yeung PP, Loupe PS, et al. A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects. Cephalalgia Int J Headache. 2018;38(13):1960\u201371.","journal-title":"Cephalalgia Int J Headache."},{"issue":"12","key":"885_CR44","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1111\/bcp.14096","volume":"85","author":"JB Fiedler-Kelly","year":"2019","unstructured":"Fiedler-Kelly JB, Cohen-Barak O, Morris DN, Ludwig E, Rasamoelisolo M, Shen H, et al. Population pharmacokinetic modelling and simulation of fremanezumab in healthy subjects and patients with migraine. Br J Clin Pharmacol. 2019;85(12):2721\u201333.","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"885_CR45","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1002\/cpdd.902","volume":"10","author":"I Cherniakov","year":"2021","unstructured":"Cherniakov I, Cohen-Barak O, Tiver R, Gillespie M, Kessler Y, Gutierrez M, et al. A Pharmacokinetic bioequivalence study of fremanezumab administered subcutaneously using an autoinjector and a prefilled syringe. Clin Pharmacol Drug Dev. 2021;10(9):1018\u201327.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"10","key":"885_CR46","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1177\/03331024211007789","volume":"41","author":"O Cohen-Barak","year":"2021","unstructured":"Cohen-Barak O, Radivojevic A, Jones A, Fiedler-Kelly J, Gillespie M, Brennan M, et al. Dose selection for fremanezumab (AJOVY) phase 3 pediatric migraine studies using pharmacokinetic data from a pediatric phase 1 study and a population pharmacokinetic modeling and simulation approach. Cephalalgia Int J Headache. 2021;41(10):1065\u201374.","journal-title":"Cephalalgia Int J Headache."},{"issue":"6","key":"885_CR47","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3390\/pharmaceutics13060785","volume":"13","author":"A Jones","year":"2021","unstructured":"Jones A, Cohen-Barak O, Radivojevic A, Fiedler-Kelly J. Scaling approaches for pediatric dose selection: the fremanezumab (AJOVY\u00ae) journey to select a phase 3 dose using pharmacokinetic data from a phase 1 study. Pharmaceutics. 2021;13(6):785.","journal-title":"Pharmaceutics"},{"key":"885_CR48","unstructured":"A randomized, placebo-controlled, single-dose study to assess the pharmacokinetics, safety, and tolerability of galcanezumab in healthy Chinese subjects. https:\/\/clinicaltrials.gov\/study\/NCT04085289. Accessed 10 Feb 2024."},{"issue":"1","key":"885_CR49","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s13238-017-0408-4","volume":"9","author":"L Liu","year":"2018","unstructured":"Liu L. Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins. Protein Cell. 2018;9(1):15\u201332.","journal-title":"Protein Cell"},{"issue":"1","key":"885_CR50","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3390\/cells12010143","volume":"12","author":"AR Pavelic","year":"2022","unstructured":"Pavelic AR, W\u00f6ber C, Riederer F, Zebenholzer K. Monoclonal antibodies against calcitonin gene-related peptide for migraine prophylaxis: a systematic review of real-world data. Cells. 2022;12(1):143.","journal-title":"Cells"},{"issue":"1","key":"885_CR51","doi-asserted-by":"publisher","first-page":"1964935","DOI":"10.1080\/19420862.2021.1964935","volume":"13","author":"E Germovsek","year":"2021","unstructured":"Germovsek E, Cheng M, Giragossian C. Allometric scaling of therapeutic monoclonal antibodies in preclinical and clinical settings. MAbs. 2021;13(1):1964935.","journal-title":"MAbs"},{"issue":"1","key":"885_CR52","first-page":"23","volume":"24","author":"DR Mould","year":"2010","unstructured":"Mould DR, Green B. Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development. BioDrugs Clin Immunother Biopharm Gene Ther. 2010;24(1):23\u201339.","journal-title":"BioDrugs Clin Immunother Biopharm Gene Ther."},{"issue":"12","key":"885_CR53","first-page":"1316","volume":"11","author":"F Anghel","year":"2021","unstructured":"Anghel F, Nitusca D, Cristodor P. Body mass index influence for the personalization of the monoclonal antibodies therapy for psoriasis. Life Basel Switz. 2021;11(12):1316.","journal-title":"Life Basel Switz."},{"issue":"1","key":"885_CR54","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s10194-020-01211-5","volume":"22","author":"JM Cohen","year":"2021","unstructured":"Cohen JM, Ning X, Kessler Y, Rasamoelisolo M, Campos VR, Seminerio MJ, et al. Immunogenicity of biologic therapies for migraine: a review of current evidence. J Headache Pain. 2021;22(1):3.","journal-title":"J Headache Pain"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-024-00885-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-024-00885-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-024-00885-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T02:10:00Z","timestamp":1714183800000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-024-00885-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,10]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["885"],"URL":"https:\/\/doi.org\/10.1007\/s13318-024-00885-5","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"type":"print","value":"0378-7966"},{"type":"electronic","value":"2107-0180"}],"subject":[],"published":{"date-parts":[[2024,3,10]]},"assertion":[{"value":"18 February 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors certify that they have no other relevant affiliations or financial involvement with any organization or entity with a financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Partial financial support was received from the Ministry of Education, Science and Technological Development, Serbia, via grant no. 175007\/contract no. 451-03-47\/2023-01\/200111.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Not applicable for review article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable for review article.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable for review article.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Not applicable for review article.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable for review article.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Slobodan Jankovi\u0107\u2014concept of the review, literature search, quality assessment of retrieved articles, writing the manuscript, control of completed manuscript. Sne\u017eana Jankovi\u0107\u2014concept of the review, literature search, quality assessment of retrieved articles, writing the manuscript, control of completed manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}